Skip to content
Eisai
-
Eisai secures USD388M deal for Chinese cancer drug Hetronifly in Japan
Hetronifly is an anti-programmed cell death protein 1 (PD-1) monoclonal antibody that has already received regulatory approval in China for treating several solid tumor types.